XML 66 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Agreements (Details) - Collaborative Arrangement, Product
 1 Months Ended 3 Months Ended
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
ApolloBio                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Territory expansion option period   3 years                  
Proceeds received in upfront payment       $ 19,400,000              
Upfront payment received       23,000,000           $ 23,000,000  
Advisory fees       960,000           960,000  
Additional revenue to be achieved                   $ 20,000,000  
Royalty period                   10 years  
Period from effective date for termination                   1 year  
Number of days written notice defore termination                   90 days  
MedImmune                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront payment received $ 27,500,000           $ 27,500,000        
Anticipated development and regulatory event based payment receivable milestones                   $ 355,000,000  
Anticipated commercial event based payment receivable milestones                   345,000,000  
Number of additional products to be developed | product     2                
Revenue recognized         $ 7,000,000            
Revenue under collaborative research and development arrangements                   1,300,000 $ 306,000
Deferred revenue       1,200,000           1,200,000  
Accounts receivable       3,000,000           3,000,000  
Roche                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Full payment           $ 8,500,000          
Hoffman-La Roche                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront payment received                 $ 10,000,000    
Previously deferred revenue recognized                   0 4,000,000
Defense Advanced Research Projects Agency (DARPA)                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue       111,000           111,000  
Accounts receivable       2,000,000           2,000,000  
Previously deferred revenue recognized                     $ 5,000,000
Term               2 years      
Base award               $ 19,600,000      
Option award               24,600,000      
Second option award               $ 11,100,000      
Funding received for research and development                   $ 376,000  
Foreign Tax Authority | ApolloBio                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Foreign corporate income taxes reducing upfront payment       2,200,000              
Foreign non-corporate income taxes reducing upfront payment       $ 1,400,000